Illumina, Inc. announced on February 19, 2025, the unveiling of a new spatial technology program designed to empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. This technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity, enabled on Illumina sequencers.
The spatial technology is planned for commercial release in 2026 and will allow researchers to examine millions of cells per experiment, featuring a capture area nine times larger and four times greater resolution than existing technologies. This capability is expected to drive expansion of spatial research in areas such as tumor microenvironments, neurobiology, and immuno-oncology.
Accompanying the spatial technology is Illumina Connected Multiomics (ICM), a new multimodal analysis platform. ICM facilitates the visualization, exploration, and analysis of multiomic datasets, including genomic, proteomic, spatial transcriptomic, epigenetic, and single-cell data, all within a single platform. Illumina also announced its intent to collaborate with the Broad Institute on a Spatial Flagship Project leveraging this new technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.